Pyxis Oncology Email Format
Biotechnology ResearchMassachusetts, United States51-200 Employees
Pyxis Oncology is a Boston-based biotechnology company focused on developing therapies that target tumor cells while countering immune suppression. Its differentiated portfolio centers on antibody-drug conjugates and immunotherapies intended for cancers that are difficult to treat, with the aim of improving patient outcomes. Described as a clinical-stage organization, Pyxis aims to serve patients and the clinical community seeking new cancer therapies. In October 2025, the company announced the appointment of Alex Kane as Senior Vice President of Investor Relations & Capital Markets. This leadership update reflects ongoing corporate development as Pyxis advances its portfolio targeting hard-to-treat cancers.